Evaluating efficacy and safety of Unani Formulation in Tinea Corporis and Tinea Cruris

A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to Evaluate the Efficacy and Safety of a Unani Formulation ? Qur?-i Sa‘fa (T) in the management of Qub ? (Tinea Corporis and Tinea Cruris). - N/A

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/11/059444

Enrollment

Registered

2023-11-02

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Qur?-i Sa‘fa: • Qur?-i Sa‘fa: Participants will be advised to crush the tablet in Ab-i K ?sni (Cichorium intybus Linn.Juice) to make liniment and apply topically on the affected site t

Eligibility

Inclusion criteria

Inclusion criteria: 1. Participants of Qub ? (Tinea corporis and Tinea cruris) having circumscribed lesions with any of the following signs and symptoms on body and limbs: A)Presence of pruritus and burning B)Presence of scales C)Presence of central clearing D)Erythematous papules 2. Participants with Positive KOH (10%) Smear Microscopy of Skin Scrapping from the active lesion for Dermatophytic hyphae.

Exclusion criteria

Exclusion criteria: The following patients will be excluded: 1) Age below 18 years and above 50 years 2) Patients with other form of tinea infection like tinea pedis, tinea manuum, tinea unguium, tinea faciei, etc. 3) Patient with other concomitant diseases like psoriasis & eczema 4) Patients who have received any topical antifungal therapy within last 2 weeks or oral antifungal therapy in the previous 4 weeks 5) Patients with known active pulmonary/ cardiovascular/ liver/ renal or neurological diseases 6) Known cases of Diabetes Mellitus or other immunocompromised disorders (HIV/ AIDS, etc.)/ Malignancies 7) Patients with long-term history of steroid, cytotoxic and immunosuppressive therapy 8) History of hypersensitivity to either clotrimazole or Qur?-i Sa‘fa 9) Pregnant or lactating women, and women desiring pregnancy 10) Participants not willing to give consent and to attend treatment schedule regularly.

Design outcomes

Primary

Measure	Time frame
1. Total Signs & Symptoms Score (TSSS) (Clinical Cure) 2. Conversion to Negative Mycology (Mycological Cure) 3. DLQI (Dermatology Life Quality Index)Timepoint: 42 Days	—

Secondary

Measure	Time frame
Systemic Safety assessmentTimepoint: 42 Days	—

Countries

India

Contacts

Public ContactDr Sultan Ul Haque

National Research Institute Of Unani Medicine For Skin Disorders

ccrumhqrsnd58@gmail.com8700027178

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026